NEW DELHI: Moderna Inc said on Thursday it had completed the enrollment of 30,000 participants in a late-stage study testing its experimental coronavirus vaccine, with over a third of the participants from communities of color.
Over 25,650 participants have so far received their second shot of the vaccine candidate, mRNA-1273, the company said.
Moderna said its study includes more than 11,000 participants from minority communities, including 6,000 Hispanic or Latin-American participants and more than 3,000 Black or African-American participants.
The company said it would evaluate the study’s risks and benefits before submitting an emergency-use application for the vaccine to the US health regulator.
The US Food and Drug Administration requires at least two months of safety data after a full vaccination regime to review applications for emergency use authorization of an experimental vaccine.
Over 25,650 participants have so far received their second shot of the vaccine candidate, mRNA-1273, the company said.
Moderna said its study includes more than 11,000 participants from minority communities, including 6,000 Hispanic or Latin-American participants and more than 3,000 Black or African-American participants.
The company said it would evaluate the study’s risks and benefits before submitting an emergency-use application for the vaccine to the US health regulator.
The US Food and Drug Administration requires at least two months of safety data after a full vaccination regime to review applications for emergency use authorization of an experimental vaccine.
